RNS Annoucements

Please visit the market news section of the London Stock Exchange website to view IBT press releases including NAV releases
2017

19

Jul 17

IBT Portfolio Update

Portfolio Update as at 30 June 2017
Read More

12

Jul 17

Dividend Declaration

The Company announced on 9 September 2016 the introduction of an annual dividend, equivalent to 4 per cent. of the Company's Net Asset Value as at the last day of the preceding financial year (31 August), to be payable through two equal distributions in January and August of each year. Shareholders approved this proposal at a General Meeting held on 29 September 2016.
Read More

14

Jun 17

Portfolio Update

Portfolio Update as at 31 May 2017
Read More

21

Apr 17

IBT Half Yearly Report

In the six months to 28 February 2017, the Net Asset Value (NAV) per Ordinary share of the Company rose from 575.1p to 656.7p, including a currency gain of £11.6m, equivalent to 30.9p per share. The NAV per share returned 16.2% including the first dividend payment of 11.5p per share, which was announced in December 2016.
Read More

22

Mar 17

Compliance with the Market Abuse Regulation

The Company announces that it is satisfied that all inside information which the Directors and the Company may have in the period leading up to the announcement of the half yearly results for the half year ended 28 February 2017 has been notified to a Regulated Information Service (RIS). The Company is therefore not prohibited from purchasing its own securities during the closed period (as defined by MAR) which ends on the date of the announcement of the Half Yearly Financial Report.
Read More

21

Feb 17

IBT Portfolio Update

Portfolio Update as at 31 January 2017
Read More
2016

13

Dec 16

Announcement of results of Annual General Meeting (AGM)

The Company gives notice that all resolutions proposed in the Notice of the Meeting were duly passed at the AGM held today. A copy of all resolutions passed as special resolutions has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.hemscott.com/nsm.do.
Read More

13

Dec 16

Dividend Declaration

The Company announced on 9 September 2016 the introduction of an annual dividend, equivalent to 4 percent. of the Company's Net Asset Value as at the last day of the preceding financial year (31 August), to be payable through two equal distributions in January and August of each year. Shareholders approved this proposal at a General Meeting held on 29 September 2016.
Read More

18

Nov 16

Director Declaration

The Company has been informed that with effect from Monday, 24 October 2016, Mrs Caroline Gulliver has been appointed as a non-executive Director of Civitas Social Housing PLC, which has been admitted to trading on the London Stock Exchange today, Friday, 18 November 2016.
Read More

4

Nov 16

Annual Financial Report Announcement of Audited Results for the year ended 31 August 2016

After a number of years of strong growth, returns for the Company were lower in the year ended 31 August 2016 with the NAV per share down 1.7%. This reflected a period of consolidation in the biotechnology sector. Although 2016 was a challenging year for the biotechnology market, our Investment Manager has outperformed the NBI for the second consecutive year.
Read More

3

Oct 16

Compliance with the Market Abuse Regulation (MAR) – Share buy backs

The Company announces that it is satisfied that all inside information which the Directors and the Company may have in the period leading up to the announcement of the Annual Financial Report for the year ended 31 August 2016 has been notified to a Regulated Information Service (RIS). The Company is therefore not prohibited from purchasing its own securities during the closed period (as defined by MAR) which ends on the date of the announcement of the Annual Financial Report.
Read More

30

Sep 16

Voting Rights and Capital

In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R the Company would like to notify the market of the following: At the close of business on the 30 September 2016, the Company had 41,342,663 Ordinary shares in issue, of which 3,795,000 were held in Treasury. Therefore the total number of voting rights in the Company was 37,547,663.
Read More

30

Sep 16

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 30 September 2016 it cancelled from treasury 295,000 Ordinary shares. Following the above cancellation, the Company holds a total of 3,795,000 of its Ordinary shares in treasury and has 37,547,663 Ordinary shares in issue (excluding treasury shares).
Read More

29

Sep 16

Announcement of results of General Meeting (GM)

The Company gives notice that all resolutions proposed in the Notice of the Meeting were duly passed at the GM held today. A copy of all resolutions passed as ordinary resolutions has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.hemscott.com/nsm.do.
Read More

13

Sep 16

Publication of Shareholder Circular

The Board of International Biotechnology Trust plc (the "Company") wishes to announce that, following the Company's announcement on 9 September 2016, the Company has today published a shareholder circular including a notice convening a general meeting in connection with the proposed introduction of dividend payments and amendments to the Company's investment objective and policy.
Read More

9

Sep 16

International Biotechnology Trust proposals to introduce dividend payments and a more flexible investment policy

Following strong long term performance, the Board of International Biotechnology Trust plc ("International Biotechnology Trust" or the "Company") today announces two proposals which it believes will be of benefit to shareholders and potential investors. These include the introduction of dividend payments and amendments to International Biotechnology Trust's investment policy to allow it to invest in unquoted funds. Both proposals will be subject to shareholder approval at a general meeting to be held on 29 September 2016 at the offices of BNP Paribas Securities Services S.C.A, 10 Harewood Avenue, London NW1 6AA (the "General Meeting").
Read More

6

Sep 16

Transaction in Own Shares

The Company announces that on 6 September 2016 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 490p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

1

Sep 16

Transaction in Own Shares

The Company announces that on 1 September 2016 it made a market purchase of 75,000 of its own Ordinary shares of 25p each, representing 0.20% of the issued share capital (excluding treasury shares). The shares were bought at 491p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

31

Aug 16

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 31 August 2016 it cancelled from treasury 130,000 Ordinary shares. Following the above cancellation, the Company holds a total of 3,965,000 of its Ordinary shares in treasury and has 37,672,663 Ordinary shares in issue (excluding treasury shares).
Read More

29

Jul 16

Transaction in Own Shares

The Company announces that on 29 July 2016 it made a market purchase of 25,000 of its own Ordinary shares of 25p each, representing 0.07% of the issued share capital (excluding treasury shares). The shares were bought at 515p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

28

Jul 16

Transaction in Own Shares

The Company announces that on 28 July 2016 it made a market purchase of 75,000 of its own Ordinary shares of 25p each, representing 0.20% of the issued share capital (excluding treasury shares). The shares were bought at 515p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

19

Jul 16

Transaction in Own Shares

The Company announces that on 19 July 2016 it made a market purchase of 100,000 of its own Ordinary shares of 25p each, representing 0.26% of the issued share capital (excluding treasury shares). The shares were bought at 486.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

12

Jul 16

Transaction in Own Shares

The Company announces that on 12 July 2016 it made a market purchase of 40,000 of its own Ordinary shares of 25p each, representing 0.11% of the issued share capital (excluding treasury shares). The shares were bought at 488.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

21

Jun 16

Transaction in Own Shares

The Company announces that on 21 June 2016 it made a market purchase of 60,000 of its own Ordinary shares of 25p each, representing 0.16% of the issued share capital (excluding treasury shares). The shares were bought at 431.0p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

17

Jun 16

Transaction in Own Shares

The Company announces that on 17 June 2016 it made a market purchase of 60,000 of its own Ordinary shares of 25p each, representing 0.16% of the issued share capital (excluding treasury shares). The shares were bought at 434.1p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

14

Jun 16

Transaction in Own Shares

The Company announces that on 14 June 2016 it made a market purchase of 100,000 of its own Ordinary shares of 25p each, representing 0.26% of the issued share capital (excluding treasury shares). The shares were bought at 435.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

26

May 16

Transaction in Own Shares

The Company announces that on 26 May 2016 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 442p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

19

Apr 16

IBT Half Yearly Report

During the six months to 29 February 2016, the net assets value (NAV) per Ordinary share of IBT fell by 17.7% from 585.1p to 481.7p. Over the same period, the Ordinary share price of IBT fell by 22.9% from 551.5p to 425.0p. This compares with a decline in the NASDAQ Biotechnology Index (NBI) of 18.0% and a fall in the FTSE All-Share Index of 1.2%.
Read More

18

Apr 16

Amendments to the Investment Management Agreement

Further to the announcement on 09 December 2015, International Biotechnology Trust plc (the Company) announces that the Directors have agreed with the Company’s investment manager, SV Life Sciences Managers LLP (the Investment Manager), amendments to the performance fees payable under an amended and restated investment management agreement (the IMA).
Read More

8

Apr 16

Transaction in Own Shares

The Company announces that on 8 April 2016 it made a market purchase of 65,000 of its own Ordinary shares of 25p each, representing 0.17% of the issued share capital (excluding treasury shares). The shares were bought at 450p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

4

Apr 16

Transaction in Own Shares

The Company announces that on 4 April 2016 it made a market purchase of 100,000 of its own Ordinary shares of 25p each, representing 0.26% of the issued share capital (excluding treasury shares). The shares were bought at 426p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

23

Mar 16

Transaction in Own Shares

The Company announces that on 23 March 2016 it made a market purchase of 75,000 of its own Ordinary shares of 25p each, representing 0.19% of the issued share capital (excluding treasury shares). The shares were bought at 415p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

8

Mar 16

Transaction in Own Shares

The Company announces that on 8 March 2016 it made a market purchase of 95,000 of its own Ordinary shares of 25p each, representing 0.24% of the issued share capital (excluding treasury shares). The shares were bought at 419p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

3

Mar 16

Transaction in Own Shares

The Company announces that on 3 March 2016 it made a market purchase of 60,000 of its own Ordinary shares of 25p each, representing 0.15% of the issued share capital (excluding treasury shares). The shares were bought at 427.3p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

9

Feb 16

Transaction in Own Shares

The Company announces that on 9 February 2016 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 383.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

3

Feb 16

Transaction in Own Shares

The Company announces that on 3 February 2016 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 410p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

2

Feb 16

Transaction in Own Shares

The Company announces that on 2 February 2016 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 425.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

1

Feb 16

Transaction in Own Shares

The Company announces that on 1 February 2016 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 432p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

29

Jan 16

Transaction in Own Shares

The Company announces that on 29 January 2016 it made a market purchase of 30,000 of its own Ordinary shares of 25p each, representing 0.08% of the issued share capital (excluding treasury shares). The shares were bought at 425p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

28

Jan 16

Transaction in Own Shares

The Company announces that on 28 January 2016 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 420p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

22

Jan 16

Transaction in Own Shares

The Company announces that on 22 January 2016 it made a market purchase of 25,000 of its own Ordinary shares of 25p each, representing 0.06% of the issued share capital (excluding treasury shares). The shares were bought at 457.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

20

Jan 16

Transaction in Own Shares

The Company announces that on 20 January 2016 it made a market purchase of 40,000 of its own Ordinary shares of 25p each, representing 0.10% of the issued share capital (excluding treasury shares). The shares were bought at 424.0p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

19

Jan 16

Transaction in Own Shares

The Company announces that on 19 January 2016 it made a market purchase of 85,000 of its own Ordinary shares of 25p each, representing 0.21% of the issued share capital (excluding treasury shares). The shares were bought at 448.0p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More
2015

24

Nov 15

Transaction in Own Shares

The Company announces that on 24 November 2015 it made a market purchase of 25,000 of its own Ordinary shares of 25p each, representing 0.06% of the issued share capital (excluding treasury shares). The shares were bought at 515.0p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

27

Oct 15

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 27 October 2015 it cancelled from treasury 800,000 Ordinary shares.
Read More

13

Oct 15

Transaction in Own Shares

The Company announces that on 13 October 2015 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 463p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

8

Oct 15

Transaction in Own Shares

The Company announces that on 8 October 2015 it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.13% of the issued share capital (excluding treasury shares). The shares were bought at 460p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

6

Oct 15

Transaction in Own Shares

The Company announces that on 6 October 2015 it made a market purchase of 40,000 of its own Ordinary shares of 25p each, representing 0.10% of the issued share capital (excluding treasury shares). The shares were bought at 472p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

1

Oct 15

Transaction in Own Shares

The Company announces that on 1 October 2015 it made a market purchase of 75,000 of its own Ordinary shares of 25p each, representing 0.19% of the issued share capital (excluding treasury shares). The shares were bought at 462p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

28

Sep 15

Transaction in Own Shares

The Company announces that on 25 September 2015 it made a market purchase of 150,000 of its own Ordinary shares of 25p each, representing 0.37% of the issued share capital (excluding treasury shares). The shares were bought at 511p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

14

Sep 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 60,000 of its own Ordinary shares of 25p each, representing 0.15% of the issued share capital (excluding treasury shares). The shares were bought at 546p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

26

Aug 15

Transaction in Own Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 26 August 2015 it cancelled from treasury 300,000 Ordinary shares.
Read More

21

Aug 15

Transaction in Own Shares

The following amendment has been made to the ‘Transaction in Own Shares’ announcement released on Friday, 21 August 2015 at 16:53 under RNS Number 8038W.
Read More

20

Aug 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 100,000 of its own Ordinary shares of 25p each, representing 0.25% of the issued share capital (excluding treasury shares). The shares were bought at 548p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

25

Jun 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 70,000 of its own Ordinary shares of 25p each, representing 0.17% of the issued share capital (excluding treasury shares). The shares were bought at 550p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

7

May 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 40,000 of its own Ordinary shares of 25p each, representing 0.10% of the issued share capital (excluding treasury shares). The shares were bought at 511.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

6

May 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 80,000 of its own Ordinary shares of 25p each, representing 0.20% of the issued share capital (excluding treasury shares). The shares were bought at 513.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

28

Apr 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 60,000 of its own Ordinary shares of 25p each, representing 0.15% of the issued share capital (excluding treasury shares). The shares were bought at 533p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

24

Apr 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.12% of the issued share capital (excluding treasury shares). The shares were bought at 556.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

17

Apr 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 45,000 of its own Ordinary shares of 25p each, representing 0.11% of the issued share capital (excluding treasury shares). The shares were bought at 557p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

14

Apr 15

IBT Half Yearly Report

I am pleased to report another excellent return for Shareholders for the six months ended 28 February 2015. The Net Asset Value (NAV) per share rose 44.5%, ending at a period high of 571.8p per share. The share price was up 57.4%, driven by very strong performance of both the unquoted and quoted parts of the portfolio, and share buybacks. This result has generated performance fees for our Investment Manager from both sections of the portfolio and a total fee of £2.0m has been accrued in these accounts.
Read More

14

Apr 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 80,000 of its own Ordinary shares of 25p each, representing 0.19% of the issued share capital (excluding treasury shares). The shares were bought at 557p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

9

Apr 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.12% of the issued share capital (excluding treasury shares). The shares were bought at 538.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

13

Mar 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 75,000 of its own Ordinary shares of 25p each, representing 0.18% of the issued share capital (excluding treasury shares). The shares were bought at 530p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

9

Mar 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 170,000 of its own Ordinary shares of 25p each, representing 0.41% of the issued share capital (excluding treasury shares). The shares were bought at 515.45p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

18

Feb 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 275,000 of its own Ordinary shares of 25p each, representing 0.65% of the issued share capital. The shares were bought at 474p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

9

Feb 15

Transaction in Own Shares

The Company announces that today it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.12% of the issued share capital. The shares were bought at 466.5p per share for cancellation.
Read More

12

Jan 15

Portfolio Update – Convergence

The Board of International Biotechnology Trust plc (the Company) notes the following unquoted portfolio event.
Read More
2014

13

Feb 16

Portfolio Update Affinium Pharmaceuticals

The Board of International Biotechnology Trust plc (the "Company") notes that agreement has been reached to sell the assets of Affinium Pharmaceuticals, an unquoted portfolio company, to Debiopharm Group.
Read More

31

Dec 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 75,000 of its own Ordinary shares of 25p each, representing 0.18% of the issued share capital. The shares were bought at 441p per share for cancellation.
Read More

18

Dec 14

Portfolio Update – OncoEthix

The Board of International Biotechnology Trust plc (IBT) notes the following positive news in relation to companies in its unquoted portfolio.
Read More

16

Dec 14

Announcement of Results of Annual General Meeting

The Company gives notice that all resolutions proposed in the Notice of the Meeting were duly passed at the AGM held today.
Read More

12

Dec 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 300,000 of its own Ordinary shares of 25p each, representing 0.70% of the issued share capital. The shares were bought at 423p per share for cancellation.
Read More

27

Nov 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 1,350,000 of its own Ordinary shares of 25p each, representing 3.07% of the issued share capital. The shares were bought at 414p per share for cancellation. Following this purchase, there are 42,667,663 Ordinary shares in issue (excluding treasury shares) and 2,720,000 Ordinary shares held in treasury.
Read More

26

Nov 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 4,550,000 of its own Ordinary shares of 25p each, representing 9.37% of the issued share capital. The shares were bought at 414p per share for cancellation.
Read More

19

Nov 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 325,000 of its own Ordinary shares of 25p each, representing 0.66% of the issued share capital. The shares were bought at 399.25p per share for cancellation.
Read More

14

Nov 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 500,000 of its own Ordinary shares of 25p each, representing 1.01% of the issued share capital. The shares were bought at 396.2p per share for cancellation.
Read More

7

Nov 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 150,000 of its own Ordinary shares of 25p each, representing 0.30% of the issued share capital. The shares were bought at 388.25p per share for cancellation.
Read More

5

Nov 14

IBT Shareholder Circular

Your attention is drawn to the letter from the Chairman of the Company which is set out on pages 2 to 3 of this document and which recommends you to vote in favour of the Resolution to be proposed at the General Meeting.
Read More

5

Nov 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 190,000 of its own Ordinary shares of 25p each, representing 0.38% of the issued share capital. The shares were bought at 391p per share for cancellation.
Read More

4

Nov 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 250,000 of its own Ordinary shares of 25p each, representing 0.50% of the issued share capital. The shares were bought at 389.35p per share for cancellation.
Read More

3

Nov 14

IBT Annual Financial Report

The following amendment has been made to the 'Annual Financial Report' announcement released on Monday, 3 November 2014 at 07:00 under RNS Number 9121V.
Read More

31

Oct 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 150,000 of its own Ordinary shares of 25p each, representing 0.30% of the issued share capital. The shares were bought at 386.75p per share for cancellation.
Read More

29

Oct 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 800,000 of its own Ordinary shares of 25p each, representing 1.54% of the issued share capital. The shares were bought at 372p per share for cancellation.
Read More

24

Oct 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 1,025,000 of its own Ordinary shares of 25p each, representing 1.93% of the issued share capital. The shares were bought at 331.65p per share for cancellation.
Read More

16

Oct 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 300,000 of its own Ordinary shares of 25p each, representing 0.56% of the issued share capital. The shares were bought at 307.1p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

15

Oct 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 550,000 of its own Ordinary shares of 25p each, representing 1.02% of the issued share capital. The shares were bought at 312.68p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

14

Oct 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 270,000 of its own Ordinary shares of 25p each, representing 0.50% of the issued share capital. The shares were bought at 312.65p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

26

Sep 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 75,000 of its own Ordinary shares of 25p each, representing 0.14% of the issued share capital. The shares were bought at 318p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

24

Sep 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.09% of the issued share capital. The shares were bought at 318p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

19

Sep 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 50,000 of its own Ordinary shares of 25p each, representing 0.09% of the issued share capital. The shares were bought at 321p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

1

Sep 14

Compliance with Model Code

In accordance with Listing Rule 15.5.1R(4), the Company confirms that it is satisfied that all inside information which the Directors and the Company have leading up to the announcement of the annual results for the year ended 31 August 2014 has been notified to a Regulatory Information Service ("RIS").
Read More

21

Jul 14

Appointment of AIFM & Depositary

The Company announces that it has entered into arrangements necessary to ensure compliance with the AIFMD. The Company's Board of Directors ("the Board") approved the appointment of SV Life Sciences Managers LLP as the Company's Alternative Investment Fund Manager ("AIFM") with effect from 21 July 2014, following the authorisation of SV Life Services Managers LLP as an AIFM by the UK's Financial Conduct Authority on 16 July 2014. The appointment is on the terms and subject to the conditions of an amended and restated investment management agreement with SV Life Sciences Managers LLP, the existing Investment Manager of the Company. The appointment is on the same commercial terms as the previous agreement but is also compliant with the new AIFMD regulatory regime. The arrangements in respect of the investment management and performance fee are unchanged.
Read More

16

Jul 14

Interim Management System

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement (“IMS”) in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 31 May 2014, together with relevant information up to the date of this announcement.
Read More

27

Jun 14

Transaction in Own Shares

The Company announces that today it made a market purchase of 800,000 of its own Ordinary shares of 25p each, representing 1.43% of the issued share capital. The shares were bought at 293.25p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

13

May 14

Notification of Major Interests in Share

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

30

Apr 14

Total Voting Rights

In accordance with the FCA's Disclosure and Transparency Rule 5.6.1R the Company would like to notify the market of the following: As at 30 April 2014, the Company's share capital consists of 55,132,663 Ordinary shares of 25p each, each Ordinary share carrying the right to one vote at general meetings. The Company holds 625,000 shares in treasury.
Read More

16

Apr 14

Transaction in Own Shares

The following amendment has been made to the 'Transaction in own shares' announcement released on Wednesday, 16 April 2014 at 17:52 under RNS Number 0256F.
Read More

3

Mar 14

Compliance with Model Code

In accordance with Listing Rule 15.5.1R(4), the Company confirms that it is satisfied that all inside information which the Directors and the Company have leading up to the announcement of the half yearly results for the half year ended 28 February 2014 has been notified to a Regulatory Information Service ("RIS").
Read More

28

Feb 14

Notification of Major Interests in Share

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

28

Feb 14

Director/PDMR Shareholding

The Company was notified today of the following changes to Directors' and PDMR's shareholdings which took place on 28 February 2014:
Read More

27

Feb 14

Notification of Major Interests in Share

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

8

Jan 14

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement ("IMS") in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 30 November 2013, together with relevant information up to the date of this announcement.
Read More
2013

11

Dec 13

Announcement of Results of AGM

The Company gives notice that all resolutions proposed in the Notice of the Meeting were duly passed at the Annual General Meeting held today.
Read More

30

Nov 13

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement (“IMS”) in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 30 November 2013, together with relevant information up to the date of this announcement.
Read More

28

Oct 13

Annual Financial Report

The information contained in this Annual Financial Report Announcement, including the 31 August 2012 comparatives, has been prepared in accordance with the applicable UK Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and with the Statement of Recommended Practice "Financial Statements of Investment Trust Companies and Venture Capital Trusts" (issued in January 2009 and adopted early). The results for the year ended 31 August 2013 are audited but do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The statutory accounts have not yet been delivered to the Registrar of Companies. Full statutory accounts for the year ended 31 August 2012 included an unqualified audit report and have been filed with the Registrar of Companies.
Read More

25

Sep 13

Portfolio Update – Ophthotech

The Board of International Biotechnology Trust plc (the "Company") notes two unquoted portfolio events.
Read More

2

Sep 13

Staff Change at Investment Manager

The Board of International Biotechnology Trust plc (the "Company") notes that the Company's Investment Manager, SV Life Sciences Managers LLP, has appointed Carl Harald Janson as Investment Manager, who will start with effect from today Monday, 2 September 2013. Carl Harald will be supported by Ailsa Craig to run the quoted side of the portfolio, and managing partner Kate Bingham will continue to manage the unquoted side of the portfolio.
Read More

21

Jun 13

Staff Change at Investment Manager

The Board of International Biotechnology Trust plc (the "Company") notes that David Pinniger has resigned his position at the Company's Manager, SV Life Sciences Managers LLP and will leave in due course. The process to find his replacement is at an advanced stage and a further announcement will be made when an appointment has been made. The Company's portfolio continues to be managed by Kate Bingham and Ailsa Craig while a replacement is found.
Read More

3

Jun 13

TSON: Announces Completion of Merger and Financing

TranS1 Inc. Announces Closing of Acquisition of Baxano, Inc. and Financing Transaction; Changes Name to Baxano Surgical, Inc.
Read More

31

May 13

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement (“IMS”) in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 31 May 2013, together with relevant information up to the date of this announcement.
Read More

6

Mar 13

Notification of Major Interests in Share

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

16

Jan 13

Directorate Change

International Biotechnology Trust plc is pleased to announce the appointment of Mr Jim Horsburgh to the Board of the Company as a non-executive Director, with effect from 1 February 2013. Mr Horsburgh will also be appointed to the Audit, Nomination and Management Engagement Committees.
Read More
2012

30

Nov 12

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement (“IMS”) in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 30 November 2012, together with relevant information up to the date of this announcement.
Read More

28

Sep 12

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 28 September 2012 it cancelled from treasury 250,000 Ordinary shares that had previously been bought back at a price of 132.25 pence per Ordinary share.
Read More

6

Sep 12

Notification of Major Interests in Shares

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

3

Jul 12

Notification of Major Interests in Shares

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

29

Jun 12

Voting Rights and Capital

In accordance with the FSA's Disclosure and Transparency Rule 5.6.1R the Company would like to notify the market of the following: As at 29 June 2012, the Company's share capital consists of 55,457,663 Ordinary shares of 25p each, each Ordinary share carrying the right to one vote at general meetings. The Company holds 550,000 Ordinary shares in treasury.
Read More

27

Apr 12

IBT Announces the Acquisition of EUSA Pharma and Ardea Biosciences

For immediate release, 27 April 2012: International Biotechnology Trust plc (“IBT” or the “Company”), the Investment Trust managed by SV Life Sciences (“SVLS”) Managers today announced the acquisition of two of its portfolio investments EUSA Pharma and Ardea Biosciences.
Read More

18

Apr 12

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 18 April 2012 it cancelled from treasury 400,000 Ordinary shares that had previously been bought back at a price of 153.00 pence per Ordinary share.
Read More

14

Mar 12

IBT – Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 14 March 2012 it cancelled from treasury 500,000 Ordinary shares that had previously been bought back at a price of 146.25 pence per Ordinary share.
Read More

22

Feb 12

IBT – Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 22 February 2012 it cancelled from treasury 250,000 Ordinary shares that had previously been bought back at a price of 148.50 pence per Ordinary share.
Read More

22

Feb 12

Change of Chairman

In accordance with Listing Rule 9.6.11R (3) & (4) the Board of International Biotechnology Trust plc hereby announces that Mr Andrew Barker will be retiring as the Chairman of the Board and as a director of the Company on Friday, 13 April 2012. It further advises that Mr Alan Clifton, a director of the Company, will succeed him as Chairman of the Board immediately following Mr Barker's retirement.
Read More

10

Feb 12

Director/PDMR Shareholding

The Company has been notified that Dr Véronique Bouchet, a non-executive Director of the Company, purchased 5,000 Ordinary 25p shares in the capital of the Company on 9 February 2012 at a price of 187.5 pence per ordinary share, representing 0.01% of the Company's issued share capital.
Read More

1

Feb 12

Disclosure of Director’s Purchase of the Company’s Shares

The Company has been notified that Mr John Aston, a non-executive Director of the Company, purchased 10,000 Ordinary 25p shares in the capital of the Company on 1 February 2012 at a price of 177.7 pence per ordinary share, representing 0.02% of the Company’s issued share capital.
Read More

27

Jan 12

Notification of Major Interests in Shares

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached .
Read More
2011

20

Dec 11

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement (“IMS”) in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 30 November 2011, together with relevant information up to the date of this announcement.
Read More

7

Dec 11

Announcement of Results of AGM

The Company gives notice that all resolutions proposed in the Notice of the Meeting were duly passed at the Annual General Meeting held today. A
Read More

25

Nov 11

Notification of Major Interests in Shares

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

22

Nov 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 22 November 2011 it cancelled from treasury 200,000 Ordinary shares that had previously been bought back at a price of 136.25 pence per Ordinary share.
Read More

17

Nov 11

Holdings in Company

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

10

Nov 11

Holdings in Company

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

4

Nov 11

Annual Information Update

As required by Prospectus Rule 5.2, all information which has been made available to the public by the Company over the previous 12 months in the United Kingdom (being the Company's Home State) which is required to be disclosed pursuant to this Rule is outlined below. In order to avoid an unnecessarily lengthy document, information is referred to in this update rather than included in full.
Read More

1

Nov 11

Transaction in own Shares

The Company announces that, on 1 November 2011, it made a market purchase of 200,000 of its own ordinary shares of 25p each, representing 0.36% of the issued share capital. The shares were bought at 149.0p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

26

Oct 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 26 October 2011 it cancelled from treasury 200,000 Ordinary shares that had previously been bought back at a price of 138.25 pence per Ordinary share.
Read More

21

Oct 11

IBT Annual Report

The information contained in this Annual Financial Report Announcement, including the 31 August 2010 comparatives, has been prepared in accordance with the applicable UK Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and with the Statement of Recommended Practice "Financial Statements of Investment Trust Companies and Venture Capital Trusts" (issued in January 2009 and adopted early).
Read More

19

Oct 11

Portfolio Update – Cadent

The issuer advises that the following replaces the portfolio update announcement released erroneously on 18 October 2011 at 17:25 under RNS Number 4187Q.
Read More

18

Oct 11

Holdings in Company

Following the disaggregation exemption notified to the FSA under the Disclosure and Transparency Rules on 17th October 2011, AXA SA and its subsidiary notifying Group entities, acting independently from their parent and from each other, no longer have any reportable holdings in International Biotechnology Trust plc on a Group aggregated basis.
Read More

30

Sep 11

Cancellation of Treasury Shares

As at 30 September 2011, the Company's share capital consists of 55,757,663 Ordinary shares of 25p each, each Ordinary share carrying the right to one vote at general meetings. The Company holds 4,400,000Ordinary shares in treasury.
Read More

30

Sep 11

Total Voting Rights

The Company announces that, on 30 September 2011, it made a market purchase of 250,000 of its own ordinary shares of 25p each, representing 0.45% of the issued share capital. The shares were bought at 145.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

29

Sep 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 29 September 2011 it cancelled from treasury 200,000 Ordinary shares that had previously been bought back at a price of 132.25 pence per Ordinary share.
Read More

19

Sep 11

Holdings in Company

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

16

Sep 11

Holdings in Company

Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.
Read More

1

Sep 11

Compliance with Model Code

In accordance with Listing Rule 15.5.1R(4), the Company confirms that it is satisfied that all inside information which the Directors and the Company have leading up to the announcement of the annual results for the year ended 31 August 2011 has been notified to a Regulatory Information Service ("RIS").
Read More

11

Jul 11

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement ("IMS") in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 31 May 2011, together with relevant information up to the date of this announcement.
Read More

7

Jul 11

Portfolio Update

The Board of International Biotechnology Trust plc (the "Company") notes that an unquoted portfolio company that, for commercial reasons, cannot currently be named has been written down by £1.5m.
Read More

1

Jul 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 29 June 2011 it cancelled from treasury 200,000 Ordinary shares that had previously been bought back at a price of 142.00 pence per Ordinary share.
Read More

24

Jun 11

Transaction in own Shares

The Company announces that, on 24 June 2011, it made a market purchase of 1,000,000 of its own ordinary shares of 25p each, representing 1.75% of the issued share capital. The shares were bought at 150.5p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

10

Jun 11

Transaction in own Shares

The Company announces that, on 10 June 2011, it made a market purchase of 1,000,000 of its own ordinary shares of 25p each, representing 1.72% of the issued share capital. The shares were bought at 151.0p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

10

Jun 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 6 June 2011 it cancelled from treasury 475,000 Ordinary shares that had previously been bought back at a price of 135.00 pence per Ordinary share.
Read More

3

Jun 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 1 June 2011 it cancelled from treasury 200,000 Ordinary shares that had previously been bought back at a price of 139.00 pence per Ordinary share.
Read More

31

May 11

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement (“IMS”) in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 31 May 2011, together with relevant information up to the date of this announcement.
Read More

16

May 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 3 May 2011 it cancelled from treasury 200,000 Ordinary shares that had previously been bought back at a price of 140.00 pence per Ordinary share.
Read More

27

Apr 11

IBT Half Yearly Report

A copy of the Half Yearly Report for the six months ended 28 February 2011 has been submitted to the National Storage Mechanism of the UK Listing Authority and will shortly be available for inspection at:www.Hemscott.com/nsm.do
Read More

26

Apr 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 8 April 2011 it cancelled from treasury 200,000 Ordinary shares that had previously been bought back at a price of 139.00 pence per Ordinary share.
Read More

18

Apr 11

Transaction in own Shares

The Company announces that, on 18 April 2011, it made a market purchase of 400,000 of its own ordinary shares of 25p each, representing 0.68% of the issued share capital. The shares were bought at 153.00p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

15

Apr 11

IBT Interim Results

I am able to report a rise in both the Net Asset Value per share ("NAV") and the share price of the Company over the half year to 28th February 2011. The NAV increased by 7.5% to 166.8 pence, which compares with 14.4% and 18.5% increases in the NASDAQ Biotechnology Index ("NBI") and the Russell 2000 Biotech Index ("RGUHSBTG") (both adjusted for the change in the Sterling/Dollar exchange rate). Broader stock markets - as measured by the FTSE All-Share index (UK) and the S&P500 index (US) - rose by 15.2% and 19.4% (the latter exchange-rate adjusted).
Read More

6

Apr 11

Portfolio Update

The Board of International Biotechnology Trust plc (the "Company") notes the following changes to the unquoted portfolio during March 2011.
Read More

30

Mar 11

Portfolio Update – Cadent

The Board of International Biotechnology Trust plc (the "Company") notes that today a definitive agreement has been signed by Align Technology, Inc (NASDAQ:ALGN) to buy the portfolio company Cadent Holdings Inc.("Cadent") for $190m.
Read More

14

Mar 11

Transaction in own Shares

The Company announces that, on 14 March 2011, it made a market purchase of 500,000 of its own ordinary shares of 25p each, representing 0.84% of the issued share capital. The shares were bought at 146.25p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

1

Mar 11

Compliance with Model Code

In accordance with Listing Rule 15.5.1R(4), the Company confirms that it is satisfied that all inside information which the Directors and the Company have leading up to the announcement of the half yearly results for the half year ended 28 February 2011 has been notified to a Regulatory Information Service ("RIS").
Read More

4

Feb 11

Cancellation of Treasury Shares

In accordance with Listing Rule 12.6.4R, the Company advises that on 3 February 2011 it cancelled from treasury 750,000 Ordinary shares that had previously been bought back at a price of 126.25 pence per Ordinary share.
Read More

1

Feb 11

Portfolio Company Update

The Board of International Biotechnology Trust plc (the "Company") notes the following developments in the unquoted portfolio during January 2011.
Read More

13

Jan 11

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement ("IMS") in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 30 November 2010, together with relevant information up to the date of this announcement.
Read More
2010

8

Dec 11

IBT AGM Proxy Votes

Summary of proxy voting totals – Annual General Meeting held on Wednesday, 8 December 2010.
Read More

30

Nov 10

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement (“IMS”) in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 30 November 2010, together with relevant information up to the date of this announcement.
Read More

24

Aug 10

Portfolio Company Update – Cadent Holdings

The Board of International Biotechnology Trust plc (the "Company") notes the following change to the value of the unquoted portfolio company Cadent Holdings.
Read More

15

Jul 10

New Investment – Gold Medal Acquisition Company

The Board of International Biotechnology Trust plc (the "Company") notes the following changes to the unquoted portfolio during June.
Read More

8

Jul 10

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement ("IMS") in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 31 May 2010, together with relevant information up to the date of this announcement.
Read More

30

Jun 10

Voting Rights and Capital

In accordance with the FSA's Disclosure and Transparency Rule 5.6.1R the Company would like to notify the market of the following: As at 30 June 2010, the Company's share capital consists of 60,357,664 Ordinary shares of 25p each, each Ordinary share carrying the right to one vote at general meetings. The Company holds 4,475,000 Ordinary shares in treasury.
Read More

24

Jun 10

Transaction in Own Shares

The Company announces that, on 24 June 2010, it made a market purchase of 200,000 of its own ordinary shares of 25p each, representing 0.33% of the issued share capital. The shares were bought at 142.00p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

1

Jun 10

Portfolio Company Update – EV3

The Board of International Biotechnology Trust plc (the "Company") notes the following development within the portfolio.
Read More

1

Jun 10

Portfolio Company Update – Affinium / RespiVert / ESBATech

The Board of International Biotechnology Trust plc (the "Company") notes the following changes to the unquoted portfolio during May.
Read More

1

Jun 10

Portfolio Company Update – RespiVert

The Board of International Biotechnology Trust plc (the "Company") notes that the portfolio company RespiVert Ltd has been sold to Centocor Ortho Biotech, Inc.
Read More

31

May 10

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement (“IMS”) in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 31 May 2010, together with relevant information up to the date of this announcement.
Read More

28

May 10

Voting Rights and Capital

In accordance with the FSA's Disclosure and Transparency Rule 5.6.1R the Company would like to notify the market of the following: As at 28 May 2010, the Company's share capital consists of 61,032,664 Ordinary shares of 25p each, each Ordinary share carrying the right to one vote at general meetings. The Company holds 3,800,000 Ordinary shares in treasury.
Read More

20

May 10

Portfolio Company Update

The Board of International Biotechnology Trust plc (the "Company") notes the following change to the value of an unquoted portfolio company, whose name cannot yet be disclosed because confidential acquisition and licensor negotiations are still in progress.
Read More

20

May 10

Transaction in Own Shares

The Company announces that, on 20 May 2010, it made a market purchase of 200,000 of its own ordinary shares of 25p each, representing 0.33% of the issued share capital. The shares were bought at 139.00p per share and the Company intends to hold these shares in treasury. These shares will only be re-issued at discounts which are less than the discounts at which the shares were bought.
Read More

4

May 10

Portfolio Company Update – Vantia / Lux / Delenex

The Board of International Biotechnology Trust plc (the "Company") notes the following changes to the unquoted portfolio during April.
Read More

30

Apr 10

Portfolio Update – Pharma

The Board of International Biotechnology Trust plc (the "Company") notes that Gold Medal Acquisitions UK Limited has made a bid for the AIM listed company Fulcrum Pharma Plc (Ticker: LON:FUL). The Company has committed up to £1.3m to the funding of a new investment in Gold Medal Acquisitions UK limited were it to be successful in its bid.
Read More

21

Apr 10

Policy on Announcements on Unquoted Portfolio Companies

The Board of International Biotechnology Trust plc (the "Company") notes a change in policy on announcements on the unquoted portfolio. From today, only material (judged by us as a 1% or more impact on the net asset value ("NAV")) investments, divestments and valuation changes will be announced in real time, with a monthly summary of all changes to be detailed in an announcement at the end of each month. There will be no change to the valuation process, with all changes to the NAV being put through daily in real time, only to the timing of announcements to the market where they are not material.
Read More

8

Apr 10

IBT Interim Results

I am pleased to report an increase in both the net asset value ("NAV") per share and share price of the Company. While newsflow from the unquoted portfolio was quiet following the sale of ESBATech in September 2009, the quoted portfolio performed well to capture the renewed investor interest in the biotechnology sector, particularly benefiting the larger-cap companies.
Read More

9

Mar 10

Portfolio Company Update – Ricerca

The Board of International Biotechnology Trust plc (the "Company") notes the following investments and change in value to the unquoted portfolio company Ricerca and a new portfolio company which has yet to decide its corporate name.
Read More

1

Mar 10

Portfolio Company Update – OSI Pharmaceuticals

MELVILLE, N.Y., Mar 01, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today confirmed that it has received an unsolicited proposal from Astellas Pharma Inc. ("Astellas") to acquire the Company for $52.00 per share.
Read More

16

Feb 10

Portfolio Company Update – Ricerca

The Board of International Biotechnology Trust plc (the "Company") notes the following changes to the unquoted portfolio company, Ricerca, and an investment in Itero Biopharma ("Itero").
Read More

15

Feb 10

Portfolio Company Update – Archemix

The Board of International Biotechnology Trust plc (the "Company") notes the following change to the value of the unquoted portfolio company Archemix.
Read More

12

Jan 10

Interim Management Statement

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement ("IMS") in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 30 November 2009, together with relevant information up to the date of this announcement.
Read More

7

Jan 10

Portfolio Company Update – EUSA Pharmaceuticals

The Board of International Biotechnology Trust plc (the "Company") notes the following change in valuation of EUSA Pharmaceuticals.
Read More

SUBSCRIBE TO OUR NEWSLETTER